Know Cancer

forgot password

A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT

Phase 2
18 Years
Open (Enrolling)
Acral Lentiginous Malignant Melanoma, Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma

Thank you

Trial Information

A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT


I. Determine the overall objective response rate (complete response and partial response) in
patients with inoperable stage III or IV melanoma harboring somatic alterations in c-KIT
treated with imatinib mesylate.


I. Determine the time to progression in patients treated with this drug. II. Determine if
c-KIT mutational status by DNA sequencing, DNA copy number status by fluorescent in situ
hybridization (FISH) or comparative genomic hybridization, and/or protein expression by
immunohistochemistry (IHC) can best predict clinical benefit from imatinib mesylate.


I. To evaluate tumors resistant to small molecule inhibitors of Kit for the development of
secondary Kit mutations or for changes in Kit copy number.

II. To evaluate for changes in Ki-67, phospho-Akt, phospho-MEK, phospho-S6, phospho STAT3,
cleaved caspase 3, IGF-1R, and Kit expression in paired tumor samples obtained from patients
treated with a small molecule inhibitor of Kit.

III. To analyze baseline and post-resistance blood samples for soluble cKIT levels, soluble
VEGFR1, soluble VEGFR2, VEGF, PlGF, FGF, and melanoma inhibitory activity (MIA) levels, and
circulating tumor cells.

IV. To analyze concomitant samples of blood and tumor for imatinib levels in patients
treated with imatinib.

OUTLINE: This is a multi-center study. Patients are stratified according to true
amplification of c-KIT by FISH vs mutations by DNA sequencing.

Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of
disease progression or unacceptable toxicity.

Tumor tissue samples or unstained tissue slides/paraffin blocks may be collected. c-KIT is
evaluated by IHC and comparative genomic hybridization.

After completion of study treatment, patients are followed up periodically.

Inclusion Criteria:

- Histologically or cytologically confirmed inoperable stage III or IV melanoma that
began on acral skin or mucosa

- Patients with cutaneous melanoma that began on sun exposed sites of the skin and
whose pathology demonstrates signs of sun damage (solar elastosis) involving the
skin surrounding their primary melanoma are eligible

- Must have sufficient tumor tissue available for FISH and DNA sequencing

- Patients must have either a true amplification of 4q12 or a detectable mutation
of c-KIT

- If no banked tumor tissue is available, or if the available banked tumor tissue
is insufficient for the necessary testing, then a repeat biopsy procedure will
be required to collect the necessary tumor sample

- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)

- No known untreated brain or epidural metastases

- Brain metastases that have been treated and deemed stable are allowed

- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

- Life expectancy greater than 3 months

- WBC ≥ 3,000/mm³

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- Patients with unexplained hyperbilirubinemia that is clinically consistent with
an inherited disorder of bilirubin metabolism (e.g., Gilbert's syndrome) may be

- AST and ALT ≤ 2.5 times ULN (5 times ULN if hepatic metastases are present)

- Creatinine ≤ 1.5 times ULN

- PT and PTT ≤ 1.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception before and during study

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to imatinib mesylate

- No concurrent uncontrolled illness including, but not limited to, any of the

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable anginapectoris

- Cardiac arrhythmia resulting in hemodynamic instability

- Intestinal malabsorption disorders

- Psychiatric illness or social situations that would limit study compliance

- Recovered to grade 1 from all prior therapies with the exception of alopecia

- At least 2 weeks since prior radiotherapy (≤ 3,000 cGy to fields including
substantial marrow)

- At least 2 weeks since prior isolated limb infusion or perfusion (must have evidence
of progression despite this therapy)

- At least 2 weeks since prior chemotherapy

- No more than 2 prior chemotherapy regimen for metastatic melanoma

- Prior therapies with vaccines, targeted agents not believed to affect the kit
proteins, cytokines, interferon-α, or intratumoral injections will NOT be considered
prior therapy unless administered with a chemotherapy drug

- No prior therapy with an inhibitor of the kit protein

- No other concurrent investigational agents

- No other concurrent anticancer agents or therapies

- No concurrent antiretroviral therapy for HIV-positive patients

- No concurrent inhibitors of CYP3A4, including any of the following:

- Fluconazole, itraconazole, ketoconazole, macrolide antibiotics (azithromycin,
clarithromycin, erythromycin, troleandomycin),midazolam, nifedipine, verapamil,
diltiazem, terfenadine, cyclosporine and cisapride

- Herbal extracts and tinctures with CYP3A4 inhibitory activity, including the

- Hydrastis canadensis (goldenseal), Hypericum perforatum (St. John's
wort),Uncaria tomentosa (cat's claw), Echinacea angustifolia roots,
Trifolium pratense(wild cherry), Matricaria, chamomilla (chamomile),
Glycyrrhiza glabra (licorice), dillapiol, hypericin, and naringenin

- No concurrent inducers of CYP3A4, including any of the following:

- Carbamazepine, phenobarbital, phenytoin, and rifampin

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective response rate (complete response and partial response)

Outcome Description:

Response will be evaluated in this study using the new international criteria proposed by the RECIST Committee. A Simon two-stage minimax design will be employed.

Outcome Time Frame:

Every 6 weeks for the first 3 courses and then every 12 weeks thereafter

Safety Issue:


Principal Investigator

Richard Carvajal

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

April 2007

Completion Date:

Related Keywords:

  • Acral Lentiginous Malignant Melanoma
  • Recurrent Melanoma
  • Stage IIIA Melanoma
  • Stage IIIB Melanoma
  • Stage IIIC Melanoma
  • Stage IV Melanoma
  • Melanoma



Memorial Sloan Kettering Cancer Center New York, New York  10021
Good Samaritan Medical Center West Palm Beach, Florida  33401
Mount Sinai Medical Center New York, New York  10029